Clinical Trial: Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

U.S., Sept. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07193615) titled 'Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)' on July 07.

Brief Summary: This is a single-arm, open-label, single-dose, dose-escalation exploratory study to evaluate the safety and tolerability of a single dose of YOLT-202 in patients with AATD and determine the optimal biologically active dose (OBD) of YOLT-202.

Study Start Date: June 18

Study Type: INTERVENTIONAL

Condition: Alpha-1 Antitrypsin Deficiency (AATD)

Intervention: DRUG: YOLT-202

The IP is administered intravenously at the predetermined dose; Administration frequency: Once

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: RenJi H...